Affordable Access

Multicenter trial of naloxone in Alzheimer's disease.

Authors
Type
Published Article
Journal
Annals of neurology
Publication Date
Volume
25
Issue
4
Pages
404–406
Identifiers
PMID: 2653175
Source
Medline

Abstract

In a double-blind, placebo-controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1-mg or 10-mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments